


MAD-ID

MAKING A DIFFERENCE
IN INFECTIOUS DISEASES®

Implementing the 2020 Vancomycin Guidelines: What every clinician needs to know



Please join MAD-ID for a free 1.5-hour enduring continuing education program focusing on implementing the vancomycin 2020 guidelines.

Goal:

Present different experiences and lessons learned implementing both the Bayesian and 2-level, post dose 1-compartment methods

Target Audience: Clinical Pharmacists, Physicians, Advanced Practice Nurses and Physician Assistants

Learning Objectives:

1. List the primary recommendations of the 2020 vancomycin guidelines
2. Discuss the advantages and disadvantages of the two preferred vancomycin AUC-based dosing methods
3. Recommend a dosing and monitoring strategy for successful implementation of vancomycin AUC-dosing at their institution based on resources and educational needs

Activity Type: Knowledge

Continuing Education Credit

Will be awarded to those participants passing a post-event learning assessment quiz.

MAD-ID is accredited by the Accreditation Council for Pharmacy Education as the provider of continuing pharmacy education. 1.5 CEU will be awarded. UAN #: 0485-0000-20-22-H01-P



This activity has been planned and implemented in accordance with the accreditation requirement and policies of the Accreditation Council for Continuing Medical Education (ACCME). MAD-ID is accredited by the ACCME to provide continuing medical education (CME) for physicians.



MAD-ID designates this “live activity” for a maximum of *1.5 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Moderator:

Michael J. Rybak, PharmD, MPH, PhD, FCCP, FIDSA, FIDP
Eugene Applebaum College of Pharmacy and Health Sciences
Wayne State University



Presenters:

Emily L. Heil, PharmD, BCPS, AQ-ID
University of Maryland Medical Center



Erin K. McCreary, PharmD, BCIDP
University of Pittsburgh Medical Center



General educational grants supporting this activity have been provided by InSightRx, Cepheid and Merck Sharp & Dohme Corp.